Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• Egile Nagusiak: Qiao Liu (Egilea), Zhen Zhou (Egilea), Xia Luo (Egilea), Lidan Yi (Egilea), Liubao Peng (Egilea), Xiaomin Wan (Egilea), Chongqing Tan (Egilea), Xiaohui Zeng (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...